These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 25267743)

  • 1. Successful Use of Dasatinib After Liver Transplantation for Imatinib-Induced Fulminant Liver Failure in Chronic Myeloid Leukemia.
    Harding DJ; MacQuillan G; Howman R; de Boer B; Adams L; Mitchell A; Jeffrey G
    J Clin Oncol; 2016 Apr; 34(11):e97-8. PubMed ID: 25267743
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
    Nacif LS; Waisberg DR; Pinheiro RS; Lima FR; Rocha-Santos V; Andraus W; D'Albuquerque LC
    J Med Case Rep; 2018 Mar; 12(1):63. PubMed ID: 29523185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should vascular effects of newer treatments be addressed more completely?
    Yang EH; Watson KE; Herrmann J
    Future Oncol; 2015; 11(14):1995-8. PubMed ID: 26198824
    [No Abstract]   [Full Text] [Related]  

  • 4. Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia.
    McGrath K; Stein B; Kalhagen L; Leighton L
    Ann Allergy Asthma Immunol; 2017 Jul; 119(1):85-86. PubMed ID: 28499700
    [No Abstract]   [Full Text] [Related]  

  • 5. Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
    Khoury HJ; Goldberg SL; Mauro MJ; Stone RM; Deininger MW; Bradley-Garelik MB; Mohamed H; Guilhot F
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):341-349.e1. PubMed ID: 27133948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].
    Martínez Pascual C; Valdés Mas M; de la Peña Moral JM; Miras López M
    Med Clin (Barc); 2011 Sep; 137(7):329-30. PubMed ID: 21074222
    [No Abstract]   [Full Text] [Related]  

  • 7. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
    Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
    Ferrero D; Cerrano M; Crisà E; Aguzzi C; Giai V; Boccadoro M
    Br J Haematol; 2017 Feb; 176(4):669-671. PubMed ID: 26914729
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
    Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
    Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial.
    Austin GM; Knight K; Bell J; Carter A; Heartin E; Watson D; Foroni L; Christmas SE; Polydoros F; Clark RE
    Br J Haematol; 2019 May; 185(4):791-793. PubMed ID: 30408160
    [No Abstract]   [Full Text] [Related]  

  • 12. Emergence of del(20q) in a patient in molecular remission of chronic myelogenous leukemia during imatinib treatment, with reduction following imatinib discontinuation.
    Numata A; Kajiyama R; Itabashi M; Ishii Y; Yamamoto W; Motohashi K; Matsumoto K; Hagihara M; Ishigatsubo Y; Fujisawa S
    Leuk Lymphoma; 2016; 57(1):201-2. PubMed ID: 25860242
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-Term Outcomes after Imatinib Mesylate Discontinuation in Chronic Myeloid Leukemia Patients with Undetectable Minimal Residual Disease.
    Yhim HY; Lee NR; Song EK; Yim CY; Jeon SY; Lee B; Kim JA; Kim HS; Cho EH; Kwak JY
    Acta Haematol; 2016; 135(3):133-9. PubMed ID: 26535871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug reaction with eosinophilia and systemic symptoms (DRESS) induced by imatinib in chronic myeloid leukemia.
    Vatel O; Aumont C; Mathy V; Petit M; Feriel J; Sloma I; Bennaceur-Griscelli A; Turhan AG
    Leuk Lymphoma; 2017 Feb; 58(2):473-474. PubMed ID: 27389710
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful Management of a Pregnant Patient With Chronic Myeloid Leukemia Receiving Standard Dose Imatinib.
    Stella S; Tirró E; Massimino M; Vitale SR; Russo S; Pennisi MS; Puma A; Romano C; DI Gregorio S; Innao V; Stagno F; DI Raimondo F; Musolino C; Manzella L
    In Vivo; 2019; 33(5):1593-1598. PubMed ID: 31471409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015.
    Gambacorti-Passerini C; Piazza R
    JAMA Oncol; 2015 May; 1(2):143-4. PubMed ID: 26181011
    [No Abstract]   [Full Text] [Related]  

  • 17. Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
    Moro MI; Manrique G; Uriarte R; Díaz L
    Leuk Lymphoma; 2014 Jul; 55(7):1684-6. PubMed ID: 24083818
    [No Abstract]   [Full Text] [Related]  

  • 18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations.
    Soysal T; Eskazan AE; Serin I; Sadri S; Keskin D; Ozgur Yurttas N; Berk S; Erdogan Ozunal I; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Ozbek U; Aydin Y
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e377-e384. PubMed ID: 31088736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series.
    Rafei H; Jabbour EJ; Kantarjian H; Sinicrope KD; Kamiya-Matsuoka C; Mehta RS; Daver NG; Kadia TM; Naqvi K; Cortes J; Konopleva M
    Leuk Lymphoma; 2019 Dec; 60(13):3292-3295. PubMed ID: 31246142
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.